What does the evidence say about Peppermint Abdominal Pain Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Peppermint Abdominal Pain Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. [Pastras Ploutarchos (2026); evidence level 2] - More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. [Pastras Ploutarchos (2026); evidence level 2] - IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. [Pastras Ploutarchos (2026); evidence level 2] - 1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. [Pastras Ploutarchos (2026); evidence level 2] - Abdominal pain must be associated with two or more of the following: defecation, change in stool frequency, or change in stool form (Rome [Foundation] IV criteria;). [Ladewski Amy M. (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.